indazoles has been researched along with Chromosomal Translocation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chisti, MM; Solano, C; Thapa, S | 1 |
| Amboldi, N; Anderson, D; Ardini, E; Avanzi, N; Ballinari, D; Bandiera, T; Banfi, P; Bosotti, R; Casero, D; Ciomei, M; De Ponti, C; Degrassi, A; Donati, D; Felder, E; Galvani, A; Harris, J; Isacchi, A; Li, G; Magnaghi, P; Menichincheri, M; Mologni, L; Orsini, P; Pesenti, E; Pulci, R; Saccardo, MB; Texido, G; Vernier, JM; Wei, G | 1 |
| Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H | 1 |
| Abe, A; Akinaga, S; Akiyama, T; Ishii, K; Ishikawa, Y; Kanda, Y; Kiyoi, H; Maeda, H; Minami, Y; Mori, Y; Naoe, T; Ozeki, K; Sato, Y; Shimizu, M; Shiotsu, Y; Tanizaki, R; Umehara, H | 1 |
1 review(s) available for indazoles and Chromosomal Translocation
| Article | Year |
|---|---|
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult | 2017 |
3 other study(ies) available for indazoles and Chromosomal Translocation
| Article | Year |
|---|---|
Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib.
Topics: Adult; Carcinoma, Renal Cell; Chromosomes, Human, X; Humans; Indazoles; Kidney Neoplasms; Male; Pyrimidines; Sulfonamides; Translocation, Genetic | 2021 |
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Enzyme Activation; Humans; Indazoles; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Mortality; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Indazoles; Isoleucine; K562 Cells; Leukemia; Male; Mice; Mice, Inbred C3H; Mice, SCID; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Threonine; Translocation, Genetic | 2009 |